**Supplementary Table 3. Relationship between circRNA and patients’ clinical features**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variables | | circRNA value | | Independent sample t-test | *p*-value |
| **Mean** | **+ SD** |
| HTN | **No** | 5.48 | 2.63 | 0.084 | 0.774 |
| **Yes** | 5.93 | .00 |
| DM | **No** | 5.17 | 2.38 | 1.748 | 0.197 |
| **Yes** | 6.51 | 2.69 |
| Renal impairment | **No** | 5.83 | 2.44 | 4.453 | 0.044\* |
| **Yes** | 2.80 | .00 |
| HSM | **No** | 3.76 | 1.05 | 2.109# | 0.123 |
| **Splenomegaly only** | 4.13 | .00 |
| **Hepatosplenomegaly** | 6.28 | 2.86 |
| **Hepatomegaly only** | 5.93 | .00 |
| Jaundice | **No** | 4.84 | 1.86 | 3.690 | 0.065 |
| **Yes** | 6.55 | 3.01 |
| Ascites | **No** | 4.01 | 1.06 | 9.535 | 0.005\*\* |
| **Yes** | 6.53 | 2.68 |
| HE | **No** | 5.23 | 2.45 | 4.319 | 0.047\* |
| **Yes** | 8.21 | .00 |
| Performance score | **ECOG 0** | 5.61 | 2.61 | 0.344 | 0.562 |
| **ECOG 1** | 4.71 | .00 |
| **ECOG 2** | . | . |  |  |
| **ECOG 3** | . | . |  |  |

#A one-way ANOVA test was used to compare more than two independent group means. \*Statistically significant at *p* < 0.05. \*\*Highly statistically significant at *p* < 0.01. ANOVA, analysis of variance; circRNA, circular RNA; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HE, hepatic encephalopathy; HSM, hepatosplenomegaly; HTN, hypertension; SD, standard deviation.